Top

Journal of Neuroinflammation

Published in:

Open Access 01-12-2022 | Opioids | Research

Delta opioid receptors on nociceptive sensory neurons mediate peripheral endogenous analgesia in colitis

Authors: Xavier Mas-Orea, Lilian Basso, Catherine Blanpied, Claire Gaveriaux-Ruff, Nicolas Cenac, Gilles Dietrich

Published in: Journal of Neuroinflammation | Issue 1/2022

Abstract

Background

Inflammatory visceral pain is endogenously controlled by enkephalins locally released by mucosal CD4⁺ T lymphocytes in mice. The present study aimed at identifying opioid receptor(s) expressed on nociceptive sensory nerves involved in this peripheral opioid-mediated analgesia.

Methods

The peripheral analgesia associated with the accumulation of CD4⁺ T lymphocytes within the inflamed colonic mucosa was assessed in conditional knockout mice specifically deleted for either of the two opioid receptors for enkephalins (i.e., µ (MOR) and δ (DOR) receptors) in Na_v1.8-expressing sensory neurons in the dextran sulfate sodium (DSS)-induced colitis model.

Results

Endogenous analgesia is lost in conditional knockout mice for DOR, but not MOR at the later phase of the DSS-induced colitis. The absence of either of the opioid receptors on sensory nerves had no impact on both the colitis severity and the rate of T lymphocytes infiltrating the inflamed colonic mucosa.

Conclusion

The key role of DOR on primary afferents in relieving intestinal inflammatory pain opens new therapeutic opportunities for peripherally restricted DOR analgesics to avoid most of the side effects associated with MOR-targeting drugs used in intestinal disorders.

Auge C, Basso L, Blanpied C, Vergnolle N, Game X, Chabot S, Lluel P, Dietrich G. Pain management in a model of Interstitial Cystitis/Bladder Pain Syndrome by a vaccinal strategy. Front Pain Res. 2021. https://doi.org/10.3389/fpain.2021.642706.CrossRef

Baamonde A, Menendez L, Gonzalez-Rodriguez S, Lastra A, Seitz V, Stein C, Machelska H. A low pKa ligand inhibits cancer-associated pain in mice by activating peripheral mu-opioid receptors. Sci Rep. 2020;10(1):18599.PubMedPubMedCentral

Baddack-Werncke U, Busch-Dienstfertig M, Gonzalez-Rodriguez S, Maddila SC, Grobe J, Lipp M, Stein C, Muller G. Cytotoxic T cells modulate inflammation and endogenous opioid analgesia in chronic arthritis. J Neuroinflammation. 2017;14(1):30.PubMedPubMedCentral

Basso L, Benamar M, Mas-Orea X, Deraison C, Blanpied C, Cenac N, Saoudi A, Dietrich G. Endogenous control of inflammatory visceral pain by T cell-derived opioids in IL-10-deficient mice. Neurogastroenterol Motil. 2020;32(2):e13743.PubMed

Basso L, Boue J, Auge C, Deraison C, Blanpied C, Cenac N, Lluel P, Vergnolle N, Dietrich G. Mobilization of CD4+ T lymphocytes in inflamed mucosa reduces pain in colitis mice: toward a vaccinal strategy to alleviate inflammatory visceral pain. Pain. 2018;159(2):331–41.PubMed

Basso L, Boue J, Bourreille A, Dietrich G. Endogenous regulation of inflammatory pain by T-cell-derived opioids: when friend turns to foe. Inflamm Bowel Dis. 2014;20(10):1870–7.PubMed

Basso L, Boue J, Mahiddine K, Blanpied C, Robiou-du-Pont S, Vergnolle N, Deraison C, Dietrich G. Endogenous analgesia mediated by CD4(+) T lymphocytes is dependent on enkephalins in mice. J Neuroinflammation. 2016;13(1):132.PubMedPubMedCentral

Basso L, Bourreille A, Dietrich G. Intestinal inflammation and pain management. Curr Opin Pharmacol. 2015;25:50–5.PubMed

Basso L, Garnier L, Bessac A, Boue J, Blanpied C, Cenac N, Laffont S, Dietrich G. T-lymphocyte-derived enkephalins reduce Th1/Th17 colitis and associated pain in mice. J Gastroenterol. 2018;53(2):215–26.PubMed

10.

Boue J, Basso L, Cenac N, Blanpied C, Rolli-Derkinderen M, Neunlist M, Vergnolle N, Dietrich G. Endogenous regulation of visceral pain via production of opioids by colitogenic CD4(+) T cells in mice. Gastroenterology. 2014;146(1):166–75.PubMed

11.

Boue J, Blanpied C, Brousset P, Vergnolle N, Dietrich G. Endogenous opioid-mediated analgesia is dependent on adaptive T cell response in mice. J Immunol. 2011;186(9):5078–84.PubMed

12.

Boue J, Blanpied C, Djata-Cabral M, Pelletier L, Vergnolle N, Dietrich G. Immune conditions associated with CD4+ T effector-induced opioid release and analgesia. Pain. 2012;153(2):485–93.PubMed

13.

Burford NT, Traynor JR, Alt A. Positive allosteric modulators of the mu-opioid receptor: a novel approach for future pain medications. Br J Pharmacol. 2015;172(2):277–86.PubMed

14.

Carbone SE, Poole DP. Inflammation without pain: Immune-derived opioids hold the key. Neurogastroenterol Motil. 2020;32(2):e13787.PubMed

15.

Feng J, Lepetre-Mouelhi S, Gautier A, Mura S, Cailleau C, Coudore F, Hamon M, Couvreur P. A new painkiller nanomedicine to bypass the blood-brain barrier and the use of morphine. Sci Adv. 2019. https://doi.org/10.1126/sciadv.aau5148.CrossRefPubMedPubMedCentral

16.

Gaveriaux-Ruff C, Nozaki C, Nadal X, Hever XC, Weibel R, Matifas A, Reiss D, Filliol D, Nassar MA, Wood JN, Maldonado R, Kieffer BL. Genetic ablation of delta opioid receptors in nociceptive sensory neurons increases chronic pain and abolishes opioid analgesia. Pain. 2011;152(6):1238–48.PubMed

17.

Gendron L, Cahill CM, von Zastrow M, Schiller PW, Pineyro G. Molecular pharmacology of delta-opioid receptors. Pharmacol Rev. 2016;68(3):631–700.PubMedPubMedCentral

18.

Guerrero-Alba R, Valdez-Morales EE, Jimenez-Vargas NN, Bron R, Poole D, Reed D, Castro J, Campaniello M, Hughes PA, Brierley SM, Bunnett N, Lomax AE, Vanner S. Co-expression of mu and delta opioid receptors by mouse colonic nociceptors. Br J Pharmacol. 2018;175(13):2622–34.PubMedPubMedCentral

19.

Hegde S, Lin YM, Fu Y, Savidge T, Shi XZ. Precision Lactobacillus reuteri therapy attenuates luminal distension-associated visceral hypersensitivity by inducing peripheral opioid receptors in the colon. Pain. 2020;161(12):2737–49.PubMedPubMedCentral

20.

Hua S, Cabot PJ. Targeted nanoparticles that mimic immune cells in pain control inducing analgesic and anti-inflammatory actions: a potential novel treatment of acute and chronic pain condition. Pain Physician. 2013;16(3):E199-216.PubMed

21.

Hughes PA, Costello SP, Bryant RV, Andrews JM. Opioidergic effects on enteric and sensory nerves in the lower GI tract: basic mechanisms and clinical implications. Am J Physiol Gastrointest Liver Physiol. 2016;311(3):G501-513.PubMed

22.

Jimenez-Vargas NN, Gong J, Wisdom MJ, Jensen DD, Latorre R, Hegron A, Teng S, DiCello JJ, Rajasekhar P, Veldhuis NA, Carbone SE, Yu Y, Lopez-Lopez C, Jaramillo-Polanco J, Canals M, Reed DE, Lomax AE, Schmidt BL, Leong KW, Vanner SJ, Halls ML, Bunnett NW, Poole DP. Endosomal signaling of delta opioid receptors is an endogenous mechanism and therapeutic target for relief from inflammatory pain. Proc Natl Acad Sci U S A. 2020;117(26):15281–92.PubMedPubMedCentral

23.

Jimenez-Vargas NN, Yu Y, Jensen DD, Bok DD, Wisdom M, Latorre R, Lopez C, Jaramillo-Polanco JO, Degro C, Guzman-Rodriguez M, Tsang Q, Snow Z, Schmidt BL, Reed DE, Lomax AE, Margolis KG, Stein C, Bunnett NW, Vanner SJ. Agonist that activates the micro-opioid receptor in acidified microenvironments inhibits colitis pain without side effects. Gut. 2021. https://doi.org/10.1136/gutjnl-2021-324070.CrossRefPubMed

24.

Kavelaars A, Heijnen CJ. T cells as guardians of pain resolution. Trends Mol Med. 2021;27(4):302–13.PubMedPubMedCentral

25.

Mace G, Blanpied C, Emorine LJ, Druet P, Dietrich G. Morphine-like activity of natural human IgG autoantibodies is because of binding to the first and third extracellular loops of the mu-opioid receptor. J Biol Chem. 1999;274(29):20079–82.PubMed

26.

Machelska H, Celik MO. Advances in achieving opioid analgesia without side effects. Front Pharmacol. 2018;9:1388.PubMedPubMedCentral

27.

Majumdar S, Grinnell S, Le Rouzic V, Burgman M, Polikar L, Ansonoff M, Pintar J, Pan YX, Pasternak GW. Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects. Proc Natl Acad Sci U S A. 2011;108(49):19778–83.PubMedPubMedCentral

28.

Manglik A, Lin H, Aryal DK, McCorvy JD, Dengler D, Corder G, Levit A, Kling RC, Bernat V, Hubner H, Huang XP, Sassano MF, Giguere PM, Lober S, Da D, Scherrer G, Kobilka BK, Gmeiner P, Roth BL, Shoichet BK. Structure-based discovery of opioid analgesics with reduced side effects. Nature. 2016;537(7619):185–90.PubMedPubMedCentral

29.

Nassar MA, Stirling LC, Forlani G, Baker MD, Matthews EA, Dickenson AH, Wood JN. Nociceptor-specific gene deletion reveals a major role for Nav1.7 (PN1) in acute and inflammatory pain. Proc Natl Acad Sci U S A. 2004;101(34):12706–11.PubMedPubMedCentral

30.

Niccum B, Moninuola O, Miller K, Khalili H. Opioid use among patients with inflammatory bowel disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021;19(5):895-907.e894.PubMed

31.

Philippe D, Dubuquoy L, Groux H, Brun V, Chuoi-Mariot MT, Gaveriaux-Ruff C, Colombel JF, Kieffer BL, Desreumaux P. Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation. J Clin Invest. 2003;111(9):1329–38.PubMedPubMedCentral

32.

Pol O, Alameda F, Puig MM. Inflammation enhances mu-opioid receptor transcription and expression in mice intestine. Mol Pharmacol. 2001;60(5):894–9.PubMed

33.

Pol O, Palacio JR, Puig MM. The expression of delta- and kappa-opioid receptor is enhanced during intestinal inflammation in mice. J Pharmacol Exp Ther. 2003;306(2):455–62.PubMed

34.

Pujo J, Petitfils C, Le Faouder P, Eeckhaut V, Payros G, Maurel S, Perez-Berezo T, Van Hul M, Barreau F, Blanpied C, Chavanas S, Van Immerseel F, Bertrand-Michel J, Oswald E, Knauf C, Dietrich G, Cani PD, Cenac N. Bacteria-derived long chain fatty acid exhibits anti-inflammatory properties in colitis. Gut. 2021;70(6):1088–97.PubMed

35.

Reaux-Le Goazigo A, Poras H, Ben-Dhaou C, Ouimet T, Baudouin C, Wurm M, Melik PS. Dual enkephalinase inhibitor PL265: a novel topical treatment to alleviate corneal pain and inflammation. Pain. 2019;160(2):307–21.PubMed

36.

Reiss D, Ceredig RA, Secher T, Boue J, Barreau F, Dietrich G, Gaveriaux-Ruff C. Mu and delta opioid receptor knockout mice show increased colonic sensitivity. Eur J Pain. 2017;21(4):623–34.PubMed

37.

Rodriguez-Gaztelumendi A, Spahn V, Labuz D, Machelska H, Stein C. Analgesic effects of a novel pH-dependent mu-opioid receptor agonist in models of neuropathic and abdominal pain. Pain. 2018;159(11):2277–84.PubMedPubMedCentral

38.

Schmid CL, Kennedy NM, Ross NC, Lovell KM, Yue Z, Morgenweck J, Cameron MD, Bannister TD, Bohn LM. Bias factor and therapeutic window correlate to predict safer opioid analgesics. Cell. 2017;171(5):1165-1175.e1113.PubMedPubMedCentral

39.

Soelberg CD, Brown RE Jr, Du Vivier D, Meyer JE, Ramachandran BK. The US opioid crisis: current federal and state legal issues. Anesth Analg. 2017;125(5):1675–81.PubMed

40.

Spahn V, Del Vecchio G, Labuz D, Rodriguez-Gaztelumendi A, Massaly N, Temp J, Durmaz V, Sabri P, Reidelbach M, Machelska H, Weber M, Stein C. A nontoxic pain killer designed by modeling of pathological receptor conformations. Science. 2017;355(6328):966–9.PubMed

41.

Stein C. New concepts in opioid analgesia. Expert Opin Investig Drugs. 2018;27(10):765–75.PubMed

42.

Stirling LC, Forlani G, Baker MD, Wood JN, Matthews EA, Dickenson AH, Nassar MA. Nociceptor-specific gene deletion using heterozygous NaV1.8-Cre recombinase mice. Pain. 2005;113(1–2):27–36.PubMed

43.

Targownik LE, Nugent Z, Singh H, Bugden S, Bernstein CN. The prevalence and predictors of opioid use in inflammatory bowel disease: a population-based analysis. Am J Gastroenterol. 2014;109(10):1613–20.PubMed

44.

Valdez-Morales E, Guerrero-Alba R, Ochoa-Cortes F, Benson J, Spreadbury I, Hurlbut D, Miranda-Morales M, Lomax AE, Vanner S. Release of endogenous opioids during a chronic IBD model suppresses the excitability of colonic DRG neurons. Neurogastroenterol Motil. 2013;25(1):39-46.e34.PubMed

45.

Verma-Gandhu M, Bercik P, Motomura Y, Verdu EF, Khan WI, Blennerhassett PA, Wang L, El-Sharkawy RT, Collins SM. CD4+ T-cell modulation of visceral nociception in mice. Gastroenterology. 2006;130(6):1721–8.PubMed

46.

Verma-Gandhu M, Verdu EF, Bercik P, Blennerhassett PA, Al-Mutawaly N, Ghia JE, Collins SM. Visceral pain perception is determined by the duration of colitis and associated neuropeptide expression in the mouse. Gut. 2007;56(3):358–64.PubMed

47.

Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain. 2015;156(4):569–76.PubMed

48.

Weibel R, Reiss D, Karchewski L, Gardon O, Matifas A, Filliol D, Becker JA, Wood JN, Kieffer BL, Gaveriaux-Ruff C. Mu opioid receptors on primary afferent nav1.8 neurons contribute to opiate-induced analgesia: insight from conditional knockout mice. PLoS ONE. 2013;8(9):e74706.PubMedPubMedCentral

49.

Zhou X, Qiao G, Ren J, Wang X, Wang S, Zhu S, Yuan Y, Morse MA, Hobeika A, Lyerly HK. Adoptive immunotherapy with autologous T-cell infusions reduces opioid requirements in advanced cancer patients. Pain. 2020;161(1):127–34.PubMed

50.

Zollner C, Mousa SA, Fischer O, Rittner HL, Shaqura M, Brack A, Shakibaei M, Binder W, Urban F, Stein C, Schafer M. Chronic morphine use does not induce peripheral tolerance in a rat model of inflammatory pain. J Clin Invest. 2008;118(3):1065–73.PubMedPubMedCentral

Title: Delta opioid receptors on nociceptive sensory neurons mediate peripheral endogenous analgesia in colitis
Authors: Xavier Mas-Orea
Lilian Basso
Catherine Blanpied
Claire Gaveriaux-Ruff
Nicolas Cenac
Gilles Dietrich
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Opioids
Opioids
Published in: Journal of Neuroinflammation / Issue 1/2022
Electronic ISSN: 1742-2094
DOI: https://doi.org/10.1186/s12974-021-02352-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Delta opioid receptors on nociceptive sensory neurons mediate peripheral endogenous analgesia in colitis

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2022

TRPV4 contributes to ER stress and inflammation: implications for Parkinson’s disease

MicroRNA-22-3p ameliorates Alzheimer’s disease by targeting SOX9 through the NF-κB signaling pathway in the hippocampus

Different gender-derived gut microbiota influence stroke outcomes by mitigating inflammation

Recombinant human plasma gelsolin reverses increased permeability of the blood–brain barrier induced by the spike protein of the SARS-CoV-2 virus

Transforming growth factor-β1 protects against LPC-induced cognitive deficit by attenuating pyroptosis of microglia via NF-κB/ERK1/2 pathways

Zika virus infection of mature neurons from immunocompetent mice generates a disease-associated microglia and a tauopathy-like phenotype in link with a delayed interferon beta response